Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Upregulation of NKG2D ligands impairs hematopoietic stem cell function in Fanconi anemia
José A. Casado, Antonio Valeri, Rebeca Sanchez-Domínguez, Paula Vela, Andrea López, Susana Navarro, Omaira Alberquilla, Helmut Hanenberg, Roser Pujol, José-Carlos Segovia, Jordi Minguillón, Jordi Surrallés, Cristina Díaz de Heredia, Julián Sevilla, Paula Rio, Juan A. Bueren
José A. Casado, Antonio Valeri, Rebeca Sanchez-Domínguez, Paula Vela, Andrea López, Susana Navarro, Omaira Alberquilla, Helmut Hanenberg, Roser Pujol, José-Carlos Segovia, Jordi Minguillón, Jordi Surrallés, Cristina Díaz de Heredia, Julián Sevilla, Paula Rio, Juan A. Bueren
View: Text | PDF
Research Article Immunology

Upregulation of NKG2D ligands impairs hematopoietic stem cell function in Fanconi anemia

  • Text
  • PDF
Abstract

Fanconi anemia (FA) is the most prevalent inherited bone marrow failure (BMF) syndrome. Nevertheless, the pathophysiological mechanisms of BMF in FA have not been fully elucidated. Since FA cells are defective in DNA repair, we hypothesized that FA hematopoietic stem and progenitor cells (HSPCs) might express DNA damage–associated stress molecules such as natural killer group 2 member D ligands (NKG2D-Ls). These ligands could then interact with the activating NKG2D receptor expressed in cytotoxic NK or CD8+ T cells, which may result in progressive HSPC depletion. Our results indeed demonstrated upregulated levels of NKG2D-Ls in cultured FA fibroblasts and T cells, and these levels were further exacerbated by mitomycin C or formaldehyde. Notably, a high proportion of BM CD34+ HSPCs from patients with FA also expressed increased levels of NKG2D-Ls, which correlated inversely with the percentage of CD34+ cells in BM. Remarkably, the reduced clonogenic potential characteristic of FA HSPCs was improved by blocking NKG2D–NKG2D-L interactions. Moreover, the in vivo blockage of these interactions in a BMF FA mouse model ameliorated the anemia in these animals. Our study demonstrates the involvement of NKG2D–NKG2D-L interactions in FA HSPC functionality, suggesting an unexpected role of the immune system in the progressive BMF that is characteristic of FA.

Authors

José A. Casado, Antonio Valeri, Rebeca Sanchez-Domínguez, Paula Vela, Andrea López, Susana Navarro, Omaira Alberquilla, Helmut Hanenberg, Roser Pujol, José-Carlos Segovia, Jordi Minguillón, Jordi Surrallés, Cristina Díaz de Heredia, Julián Sevilla, Paula Rio, Juan A. Bueren

×

Figure 3

Analysis of NKG2D-L levels in fresh BM CD34+ cells from HDs and patients with FA.

Options: View larger image (or click on image) Download as PowerPoint
Analysis of NKG2D-L levels in fresh BM CD34+ cells from HDs and patients...
(A) Representative contour plot analyses of NKG2D-L in CD34+ cells from HDs (n = 3) and patients with FA (n = 3). SSC-A, side scatter area. (B) Proportion of CD34+ cells positive for NKG2D-L in BM from HDs (n = 7) and patients with FA (n = 23). Light blue data points correspond to FA BM samples from 1 single analysis (n = 20). Dark blue (FA-610), green (FA-611), and gray (FA-655) data points correspond to BM samples from the same patient with FA analyzed at different time points (n = 27 total FA samples). Additional details on the FA and HD samples are provided in Tables 1 and 2. (C) Analysis of the percentage of CD34+ cells in BM samples from HDs and patients with FA. FA samples were classified into 2 groups according to NKG2D-L levels, using as a cutoff the maximum percentage of NKG2D-Ls determined in HD samples (12%; see Tables 1 and 2). (HD, n = 7; FA >12% NKG2D-L+, n = 22; FA ≤12% NKG2D-L+, n = 5). P values were determined by Kruskal-Wallis test followed by Dunn’s multiple-comparison test. (D) Correlation analysis between the percentage of CD34+ cells in BM and the proportion of CD34+ cells positive for NKG2D-Ls in samples from HDs and patients with FA (data point colors as in B, n = 27) and HDs (red data points, n = 7). Mean values ± SEM are indicated for each group in B and C, and significance was calculated by unpaired t test. Spearman’s correlation test was applied for assessment of HD and FA samples and also only for FA samples. Dashed lines indicate the lowest percentage of CD34+ cells and the highest proportion of NKG2D-L expression in BM CD34+ cells from HDs.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts